A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
The ability of CMV–specific ELISPOT assay to predict outcome of low level CMV reactivation in hematopoietic cell transplant recipients
2016
Open Forum Infectious Diseases
Background. CMV infection causes significant morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). CMV cell mediated immunity, as assessed by T cells production of interferon gamma (IFN-γ) and other cytokines, is considered as a major pathway to control CMV replication. We aimed to evaluate the ability of a CMV-specific ELISPOT assay to predict the outcome of low-level CMV reactivation in allo-HCT recipients. Methods. In this prospective observational study, we
doi:10.1093/ofid/ofw172.1845
fatcat:whjpn3xsdbge5iod54qoltgamy